This post is from a suggested group
Host Cell Protein (HCP) Testing
In the production of biologics, HCP testing is the critical gatekeeper for patient safety. By 2026, the industry has shifted from "Process-Specific" ELISA assays to Automated Mass Spectrometry (MS) workflows. This allows manufacturers to detect and quantify individual, high-risk proteins that might be missed by traditional methods. This specificity is vital because certain "hitchhiker proteins" can act as adjuvants, unintentionally stimulating the patient's immune system to attack the drug itself, leading to treatment failure or severe allergic reactions.
Moreover, the integration of HCP testing into Continuous Manufacturing lines has transformed quality control. Instead of waiting for a batch to be completed to test for impurities, "at-line" MS sensors provide real-time feedback to the bioreactor. If HCP levels exceed a certain threshold, the system automatically adjusts the purification parameters (such as chromatography flow rates) to compensate. This "Quality-by-Design" approach reduces the risk of expensive batch rejections and ensures that life-saving medications…
Great technology for these kids